Rani Therapeutics
RANI
34 hedge funds and large institutions have $11.8M invested in Rani Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 6 closing their positions.
434% more call options, than puts
Call options by funds: $155K | Put options by funds: $29K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
10% more capital invested
Capital invested by funds: $10.7M → $11.8M (+$1.07M)
1.44% less ownership
Funds ownership: 13.26% → 11.82% (-1.4%)
8% less funds holding
Funds holding: 37 → 34 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$127K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$110K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$104K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$103K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$68.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$877K |
| 2 |
TPC
Takeda Pharmaceutical Company
Tokyo,
Japan
|
-$640K |
| 3 |
Renaissance Technologies
New York
|
-$252K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$169K |
| 5 |
ASGS
Alpha Square Group S
New York
|
-$104K |
RANI Hedge Fund Activity: Q2 2024 in Review
34 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q2 2024, worth a combined $11.8M — up 9.9% from $10.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of RANI and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 10 added.
The largest buyer was Vanguard Group, adding an estimated $127K. The largest seller was United Services Automobile Association, cutting an estimated $877K.
- 34 institutional investors held Rani Therapeutics (RANI) as of Q2 2024, down from 37 in Q1 2024.
- Funds reported $11.8M of Rani Therapeutics stock for Q2 2024, up 9.9% quarter-over-quarter.
- 3 funds opened new Rani Therapeutics positions in Q2 2024 and 6 closed out, a net change of -3 holders.
- The largest Rani Therapeutics buyer in Q2 2024 was Vanguard Group, an estimated $127K added.
- The largest Rani Therapeutics seller in Q2 2024 was United Services Automobile Association, an estimated $877K sold.
Based on aggregated 13F filings for Q2 2024.